01—Abstract
Summary
Summary of the 20-F/A filed August 8, 2019. Cited figures are marked; the original filing is the authoritative source.
This Amendment No. 1 on Form 20-F/A by James Hardie Industries plc amends the Company's 2019 Form 20-F for the fiscal year ended 31 March 2019, originally filed on 21 May 2019.
The amendment does not change financial results. It revises the Controls and Procedures section (Item 15) to add a disclosure that management's assessment of internal control over financial reporting excluded Fermacell, the business acquired on 3 April 2018, as permitted by SEC rules for acquired businesses. The same information was already in Item 3.D of the original filing, and the amendment adds the related attestation report of Ernst & Young LLP along with amended Section 302 and 906 certifications.
The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls were effective at a reasonable assurance level as of 31 March 2019. Management concluded that internal control over financial reporting was effective as of 31 March 2019, and Ernst & Young LLP expressed an unqualified opinion on that effectiveness. The excluded Fermacell business accounted for 17.2%a of total assets, 37.0% of net assets, 13.3% of revenues and 2.1% of operating income in the consolidated financial statements for the year.
Management reported no changes in internal control over financial reporting during the period that materially affected, or were reasonably likely to materially affect, those controls. For investors, the key takeaway is that the amendment is a disclosure-only correction and does not alter the company's reported financial position. The notable detail is the size of the carve-out: Fermacell represents a large share of total and net assets despite contributing a smaller share of revenues and operating income.
02—Key points
Key Highlights
- Filing type: Amendment No. 1 on Form 20-F/A, amending the 2019 Form 20-F for the fiscal year ended 31 March 2019 (originally filed 21 May 2019).
- Only the Section 302 and 906 certifications (Exhibits 12.1, 12.2 and 13.1) were amended and filed with this amendment.
- Internal control over financial reporting was concluded effective as of 31 March 2019, with an unqualified opinion from Ernst & Young LLP.
- Management's assessment excluded Fermacell, acquired 3 April 2018, as permitted by SEC rules for acquired businesses.
- Fermacell represented 17.2% of total assets, 37.0% of net assets, 13.3% of revenues and 2.1% of operating income.
- Disclosure controls and procedures were concluded effective at a reasonable assurance level as of 31 March 2019.
- Management reported no changes in internal control over financial reporting during the period that materially affected or were reasonably likely to materially affect those controls.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2019, James Hardie Industries kept $0.09.
- Revenue$2.51B100.0%
- Cost of revenue−$1.68B66.8%
- Gross profit$831.0M33.2%
- Operating costs−$479.4M19.1%
- Operating income$351.6M14.0%
- Interest, other & tax−$122.8M4.9%
- Net income$228.8M9.1%
Where FY2019 revenue went
$2.51B- Cost of revenue: $1.68B, 67% of revenue
- SG&A: $403.6M, 16% of revenue
- Net income: $228.8M, 9.1% of revenue
- R&D: $37.9M, 1.5% of revenue
- Other operating costs: $37.9M, 1.5% of revenue
- Interest, other & tax: $122.8M, 4.9% of revenue
Kept 9.1% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-K/AFY2019filed August 8, 2019Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $2.51B$2.05B | +22.0% |
| Cost of Revenue | $1.68B$1.32B | +26.5% |
| Gross Profit | $831.00M$730.20M | +13.8% |
| R&D Expenses | $37.90M$33.30M | +13.8% |
| SG&A Expenses | $403.60M$311.30M | +29.6% |
| Operating Income | $351.60M$229.20M | +53.4% |
| Interest Expense | $54.20M$32.90M | +64.7% |
| Net Income | $228.80M$146.10M | +56.6% |
| EPS (Basic) | $0.52$0.33 | +57.6% |
| EPS (Diluted) | $0.52$0.33 | +57.6% |
| Shares Outstanding (Basic) | 441.90M441.20M | +0.2% |
| Shares Outstanding (Diluted) | 443.00M442.30M | +0.2% |
05—Questions
Frequently Asked Questions
Why was this amendment filed?
The amendment adds a disclosure, as permitted by SEC rules for acquired businesses, that the assessment of internal control over financial reporting for the year ended 31 March 2019 did not include Fermacell. The information was already in Item 3.D of the original 2019 Form 20-F and is now also in Item 15, together with the auditor's attestation report, which required amended certifications.
Did the amendment change the company's financial results?
The filing does not present any changes to financial results. It amends only the Controls and Procedures disclosure and the related certifications, which are the only exhibits amended and filed in this Amendment No. 1.
What did management conclude about internal controls?
Management concluded that internal control over financial reporting was effective as of 31 March 2019 using the COSO 2013 framework, and that disclosure controls and procedures were effective at a reasonable assurance level as of the same date.
What is Fermacell and how large is its role in the financials?
Fermacell is the business held by XI (DL) Holdings GmbH, now named James Hardie Europe Holdings 2 GmbH, which the company acquired on 3 April 2018. The filing states it comprised 17.2% of total assets, 37.0% of net assets, 13.3% of revenues and 2.1% of operating income for the fiscal year ended 31 March 2019.
Did the auditor give an opinion on internal controls?
Yes. Ernst & Young LLP stated that James Hardie Industries plc maintained, in all material respects, effective internal control over financial reporting as of 31 March 2019, based on the COSO criteria. The auditor's opinion excluded the internal controls of Fermacell, consistent with management's assessment.
06—Continue